Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAVCR1 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
HAVCR1 siRNA is a small interfering RNA (siRNA) designed to knock down the expression of Hepatitis A Virus Cellular Receptor 1 (HAVCR1, also known as TIM-1). In preclinical research, HAVCR1 siRNA has been utilized to investigate the role of HAVCR1 in various cancers, including breast cancer and hepatocellular carcinoma. Knockdown of HAVCR1 in breast cancer cell lines (such as MCF-7 and MDA-MB-231) has been shown to alter cellular functions, including enhancing cell adhesion, proliferation, and migration, reducing tight junction integrity, and increasing endothelial cell invasion across the blood-brain barrier. It is primarily used as a research-use-only laboratory reagent.
- Other names
- anti-HAVCR1 siRNAanti-HAVCR-1 siRNAanti-HAVCR 1 siRNAHAVCR1 small interfering RNAHAVCR-1 small interfering RNAHAVCR 1 small interfering RNAsi-HAVCR1si-HAVCR-1si-HAVCR 1
02
Targets
TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1)
Beyond the preview
Go deeper on HAVCR1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAVCR1 siRNA.